{"name":"Legend Biotech Corporation","slug":"legend-biotech","ticker":"LEGN","exchange":"NASDAQ","domain":"legendbiotech.com","description":"Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for","hq":"Somerset, NJ","founded":2012,"employees":"2900","ceo":"Ying Huang","sector":"Biotechnology / Cell Therapy","stockPrice":18.24,"stockChange":0.25,"stockChangePercent":1.39,"marketCap":"$3.4B","metrics":{"revenue":1028899968,"revenueGrowth":64.2,"grossMargin":20,"rdSpend":0,"netIncome":-296800000,"cash":948600000,"dividendYield":0,"peRatio":15.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ciltacabtagene autoleucel (cilta-cel) patent cliff ($1.5B at risk)","drug":"ciltacabtagene autoleucel (cilta-cel)","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"idecabtagene vicleucel (ide-cel) patent cliff ($2.2B at risk)","drug":"idecabtagene vicleucel (ide-cel)","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-06-01","type":"regulatory","headline":"FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","summary":"The FDA has approved ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma.","drugName":"ciltacabtagene autoleucel (cilta-cel)","sentiment":"positive"},{"date":"2022-12-15","type":"earnings","headline":"Legend Biotech Reports Third Quarter 2022 Financial Results","summary":"Legend Biotech reported its third quarter 2022 financial results, with revenue increasing by 25% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Legend Biotech Announces Collaboration with Janssen to Develop Cell Therapies for Solid Tumors","summary":"Legend Biotech has entered into a collaboration with Janssen to develop cell therapies for the treatment of solid tumors.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQRzdWbTIyTzRSYnIwUnlpNGo4cmV3ZEJQaXNpbHhTRjNlbFpqYnM3bGgyLVZSUHZhSl9XcG9jbFY4U2tDX1hrM2Z0NG5WbmlBQUpxLXA2QkhpQXNVcEJObDQtTXhoNHMyd21OQUtnY2dXNWhXXzBfcDdCN0U3ZXJXeVFmUTFPd2dtS1AtM2YxbEotUQ?oc=5","date":"2026-03-30","type":"deal","source":"Insider Monkey","summary":"11 High Growth Healthcare Stocks to Buy Now - Insider Monkey","headline":"11 High Growth Healthcare Stocks to Buy Now","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQY25CRllUR3pseUdIV3I0ZEtPajVTd1RwNFBsLTlKZlROdUJ6RkNwMmlYWDBST3d1b0dOaWpVTXU0S1A2bXYxWFZicXVWSTA4V0RITHNPdkFvY0ZYZFJWSU05VDhVaUxkcDFmSmdzeWJIak43UjVKRk96dVBxRW92SkVhUzFBOXNJa3I2TWdtaUxwZ3VpMzR1Rmh2YUdUcTFjWGxsT0QtYWMwa3NNTEtMNWtCYlhjLUlTT2lGVndxYXl6UXFyZzI3R2NDM3JYU1BSemo0Mm11REIydHd3TW51OFZZX3QtTUlOS1RkNkZwOWRRU1ZtWkY3SGdRc1drUQ?oc=5","date":"2026-02-23","type":"earnings","source":"Sahm","summary":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Sahm","headline":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Legend Biotech Corporation's (NASDAQ:LEGN) 26% Share Price Plunge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Legend Biotech Corporation's (NASDAQ:LEGN) 26% Share Price Plunge","sentiment":"neutral"},{"date":"2026-02-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOZW1yUDFDb2V0V3RmSjFvNGM2TlV0eENyTVhLTlpIeGRNelN1ZXVRLVJuWi03QWhCbHpnOG1KT3BxM3djYUZiZWNjQXhjUy1qRnZCcnVwVnVQTnNKQjZrdXdyZjUxV0l6LVVVYnh4SDNKRzNOWE5JSENLMTdyc08wQ1hnT1pFUkhaaVhSYTR0dG1XY19tOGgtU2hVME5jMVJ0MnBz?oc=5","date":"2025-11-25","type":"pipeline","source":"Seeking Alpha","summary":"Legend Biotech: Is Carvykti Changing Cancer Treatment Forever? (NASDAQ:LEGN) - Seeking Alpha","headline":"Legend Biotech: Is Carvykti Changing Cancer Treatment Forever? (NASDAQ:LEGN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNeTlPMWJaQVYxdVRmRG5rOFM5c3NPckR5ZVg5OU9BbVprVTBueDdvWkVJdGF2Z3ZlV01tckdCb2p6ZkRWMHFtcDZCNkdCbXNGSXdSVHhZa1JFQ3ZLYU5vODhLcFpEYXJFekEzUEpWazMzVGFaZVp5bm9ESVNIT0FBUlRPSmMxWDktSnJXa2RuRnduQkwtVVgtT2ctYW94T2ZFTXBGa2kwRWpVQ1RCVWY5bEIyRGo4U2JwTnFhMUlLU3E1RlkxajNPTG9Gdzl2U0s3RVpQTTdXUGwtLWc?oc=5","date":"2025-11-12","type":"earnings","source":"globenewswire.com","summary":"Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights - globenewswire.com","headline":"Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOOV92VWEzU3JVazVUeUpDRlh3a3UxMTJvb3FLenl6SXRMT2hVX0lPS2VTRlRyaElHOHp4QVF0QkNGMDc3NHJkaWFDNmI1UWVfRFQ0VWJuTVVRbmd5Ml9TODdqNmZsSFdqbURDUTA5R2FJbUtObTVNVUVCQ01KQm0wZ3ZBaVkxa21DY0Jnd1NzNnBfbmtqUWxPYXdoNWo3NkRfbWRoZWZiei1XT3ZqdTJwWE5wUGwtRkV6ZG11cm03RUJUdTVOOWc?oc=5","date":"2025-08-14","type":"earnings","source":"Seeking Alpha","summary":"Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade - Seeking Alpha","headline":"Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-04","type":"pipeline","source":"simplywall.st","summary":"Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money - simplywall.st","headline":"Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9LWTQwZGRpY1Z5MmpfM1EyVVpEc0RxdU1VZk5Sd05sM3J0OW80d3hISVRpazFFVnhJLU1FX29rSHQ0UGJvbGZOanVydmd5RHIwdWxSaVRqQm92YlUtU2JYeEZ4eWJkeEhmSVBxU2sycXNiODRJeHZfWk9DVDZ4MG8?oc=5","date":"2025-07-15","type":"deal","source":"U.S. News Money","summary":"7 Best Biotech Stocks to Buy for 2025 - U.S. News Money","headline":"7 Best Biotech Stocks to Buy for 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE93R2Z2YnBZdnBNa2x6RjBTUVNsa1dzMzlEQmI0ZF9iWTJLemlQOHJEenpRenJmY0FfZXl3UG4wX2xabWE2ZGFKY2xnWk5TUXdmQjNv?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"LEGN Stock Price, News & Analysis | Legend Biotech - Stock Titan","headline":"LEGN Stock Price, News & Analysis | Legend Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMGtMZ3hUR2FPUVdNOXcxSjNJRVRRSDR4aktJaWU1MmpIRGhJQnZkbkt0R0ZmM255NGg1c094dktHc2pKZkd5Smw3aTlONmVFUjFqX2FYTWVNUmd4Q014RWl4NUE0SjhwWFRpU3dhb08zRFo3LW5pSmc1eFFMbEJLcTZMNEstY0c5?oc=5","date":"2025-02-23","type":"deal","source":"Yahoo Finance","summary":"Why Legend Biotech Corporation (LEGN) is the Most Oversold Pharma Stock to Buy According to Analysts - Yahoo Finance","headline":"Why Legend Biotech Corporation (LEGN) is the Most Oversold Pharma Stock to Buy According to Analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQNDFkWWxRS1VRemZGV2JvYkxMNk9neHVTbXBOMDlQbThqWkVvM2Fqbl9ub0JWSHR4T3J5LXJ1WG5fU3Z2NXFLTWxiRjNNWllROFFIeXJydGhkbHh3RmllZW4tMXlqNERzWTdQT1RoZWNWLVhua2dVWWRVcms2UlhkNGVhdzdMZC1YdXNKbi1nQU5EMU0zOVBDTHE3Rm9KNzYzZGxR?oc=5","date":"2024-07-15","type":"deal","source":"Fierce Pharma","summary":"J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer - Fierce Pharma","headline":"J&J’s CAR-T partner Legend Biotech reportedly receives buyout offer","sentiment":"neutral"}],"patents":[{"drugName":"ciltacabtagene autoleucel (cilta-cel)","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"idecabtagene vicleucel (ide-cel)","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":2200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol-Myers Squibb","Gilead Sciences","Janssen Pharmaceuticals"],"therapeuticFocus":["Oncology","Cell Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":2900,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":18.24,"previousClose":17.99,"fiftyTwoWeekHigh":45.3,"fiftyTwoWeekLow":16.24,"fiftyTwoWeekRange":"16.24 - 45.297","fiftyDayAverage":18.21,"twoHundredDayAverage":28.45,"beta":0.08,"enterpriseValue":6119355904,"forwardPE":15.9,"priceToBook":3.37,"priceToSales":3.28,"enterpriseToRevenue":5.95,"enterpriseToEbitda":-48.15,"pegRatio":0,"ebitda":-127100000,"ebitdaMargin":-12.4,"freeCashflow":-133987504,"operatingCashflow":-100200000,"totalDebt":413700000,"debtToEquity":41.3,"currentRatio":1.96,"returnOnAssets":-5,"returnOnEquity":-29.1,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":16,"targetMeanPrice":57.22,"targetHighPrice":86,"targetLowPrice":21,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.3,"institutionHeldPercent":50.4,"sharesOutstanding":184955648,"floatShares":163193866,"sharesShort":17985159,"shortRatio":9.73,"shortPercentOfFloat":9.7,"epsTrailing":-1.62,"epsForward":1.15,"revenuePerShare":5.58,"bookValue":5.42,"officers":[{"age":52,"name":"Dr. Ying  Huang Ph.D.","title":"CEO & Director"},{"age":53,"name":"Mr. Carlos  Santos","title":"Chief Financial Officer"},{"age":40,"name":"Ms. Jessie  Yeung M.B.A.","title":"Vice President of Finance, Investor & Public Relations"},{"age":null,"name":"Mr. James  Pepin J.D.","title":"General Counsel"},{"age":51,"name":"Ms. Ananda Elizabeth Martin Esq., J.D.","title":"Global Compliance Officer"},{"age":null,"name":"Dr. Guowei  Fang Ph.D.","title":"President of Research & Development"},{"age":null,"name":"Mr. Birk  Vanderweeen","title":"Senior Vice President of Global Manufacturing & Supply"},{"age":53,"name":"Mr. Alan S. Bash","title":"President of CARVYKTI®"}],"industry":"Biotechnology","irWebsite":"","website":"https://legendbiotech.com","phone":"737 317 5050"}}